| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
47,262,000 |
| Market
Cap: |
21.22(B) |
| Last
Volume: |
372,829 |
Avg
Vol: |
445,636 |
| 52
Week Range: |
$274.7 - $456.84 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 1207 |
| Guru Rank Value : -1 |
| Guru Occurances : 3 |
|
|
|
|
|
| |
|
Company Profile United Therapeutics is a biotechnology company. Through its subsidiary, Lung Biotechnology PBC, Co. is focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Co. markets and sells the following commercial therapies to treat pulmonary arterial hypertension: Remodulin® (treprostinil) Injection; Tyvaso® (treprostinil) Inhalation Solution; Orenitram® (treprostinil) Extended-Release Tablets; and Adcirca® (tadalafil) Tablets. In the U.S., Co. also markets and sells an oncology product, Unituxin® (dinutuximab) Injection, for the treatment of high-risk neuroblastoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
488,935 |
593,616 |
889,633 |
1,941,826 |
| Total Sell Value |
$206,047,056 |
$237,821,451 |
$341,590,086 |
$634,927,635 |
| Total People Sold |
8 |
10 |
14 |
14 |
| Total Sell Transactions |
65 |
76 |
112 |
285 |
| End Date |
2025-08-10 |
2025-05-09 |
2024-11-08 |
2023-11-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Rothblatt Martine A |
Chairperson & CEO |
• • – |
2025-11-07 |
4 |
AS |
$446.42 |
$1,793,008 |
D/D |
(4,000) |
130 |
|
- |
|
| Rothblatt Martine A |
Chairperson & CEO |
• • – |
2025-11-07 |
4 |
OE |
$120.26 |
$481,040 |
D/D |
4,000 |
4,130 |
|
- |
|
| Rothblatt Martine A |
Chairperson & CEO |
• • – |
2025-11-06 |
4 |
AS |
$448.14 |
$1,794,308 |
D/D |
(4,000) |
130 |
|
-1% |
|
| Rothblatt Martine A |
Chairperson & CEO |
• • – |
2025-11-06 |
4 |
OE |
$120.26 |
$481,040 |
D/D |
4,000 |
4,130 |
|
- |
|
| Rothblatt Martine A |
Chairperson & CEO |
• • – |
2025-11-05 |
4 |
AS |
$432.53 |
$1,751,922 |
D/D |
(4,000) |
130 |
|
0% |
|
| Rothblatt Martine A |
Chairperson & CEO |
• • – |
2025-11-05 |
4 |
OE |
$120.26 |
$481,040 |
D/D |
4,000 |
4,130 |
|
- |
|
| Rothblatt Martine A |
Chairperson & CEO |
• • – |
2025-11-04 |
4 |
AS |
$432.75 |
$1,736,501 |
D/D |
(4,000) |
130 |
|
3% |
|
| Rothblatt Martine A |
Chairperson & CEO |
• • – |
2025-11-04 |
4 |
OE |
$120.26 |
$481,040 |
D/D |
4,000 |
4,130 |
|
- |
|
| Edgemond James |
CFO AND TREASURER |
• – – |
2025-11-04 |
4 |
AS |
$432.09 |
$9,157,821 |
D/D |
(21,000) |
8,118 |
|
3% |
|
| Edgemond James |
CFO AND TREASURER |
• – – |
2025-11-04 |
4 |
OE |
$146.03 |
$3,066,630 |
D/D |
21,000 |
29,118 |
|
- |
|
| Rothblatt Martine A |
Chairperson & CEO |
• • – |
2025-11-03 |
4 |
AS |
$433.78 |
$1,753,194 |
D/D |
(4,000) |
130 |
|
2% |
|
| Rothblatt Martine A |
Chairperson & CEO |
• • – |
2025-11-03 |
4 |
OE |
$120.26 |
$481,040 |
D/D |
4,000 |
4,130 |
|
- |
|
| Causey Christopher |
|
– • – |
2025-11-03 |
4 |
GD |
$0.00 |
$0 |
D/D |
450 |
4,190 |
|
- |
|
| Benkowitz Michael |
PRESIDENT AND COO |
• – – |
2025-11-03 |
4 |
AS |
$417.50 |
$9,658,073 |
I/I |
(22,500) |
0 |
|
2% |
|
| Benkowitz Michael |
PRESIDENT AND COO |
• – – |
2025-11-03 |
4 |
OE |
$135.42 |
$3,130,504 |
I/I |
22,500 |
7,875 |
|
- |
|
| Rothblatt Martine A |
Chairperson & CEO |
• • – |
2025-10-31 |
4 |
AS |
$447.83 |
$1,801,398 |
D/D |
(4,000) |
130 |
|
1% |
|
| Rothblatt Martine A |
Chairperson & CEO |
• • – |
2025-10-31 |
4 |
OE |
$120.26 |
$481,040 |
D/D |
4,000 |
4,130 |
|
- |
|
| Rothblatt Martine A |
Chairperson & CEO |
• • – |
2025-10-30 |
4 |
AS |
$447.14 |
$1,795,837 |
D/D |
(4,000) |
130 |
|
-1% |
|
| Rothblatt Martine A |
Chairperson & CEO |
• • – |
2025-10-30 |
4 |
OE |
$120.26 |
$481,040 |
D/D |
4,000 |
4,130 |
|
- |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2025-10-30 |
4 |
AS |
$447.34 |
$4,953,760 |
D/D |
(11,000) |
36,781 |
|
-1% |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2025-10-30 |
4 |
OE |
$135.42 |
$1,489,620 |
D/D |
11,000 |
47,781 |
|
- |
|
| Rothblatt Martine A |
Chairperson & CEO |
• • – |
2025-10-29 |
4 |
AS |
$433.31 |
$1,743,112 |
D/D |
(4,000) |
130 |
|
-1% |
|
| Rothblatt Martine A |
Chairperson & CEO |
• • – |
2025-10-29 |
4 |
OE |
$120.26 |
$481,040 |
D/D |
4,000 |
4,130 |
|
- |
|
| Rothblatt Martine A |
Chairperson & CEO |
• • – |
2025-10-28 |
4 |
AS |
$413.58 |
$1,661,555 |
D/D |
(4,000) |
130 |
|
8% |
|
| Rothblatt Martine A |
Chairperson & CEO |
• • – |
2025-10-28 |
4 |
OE |
$120.26 |
$481,040 |
D/D |
4,000 |
4,130 |
|
- |
|
2254 Records found
|
|
Page 1 of 91 |
|
|
5.09 (1.12%) 
